CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

Ali Rihani; Bram de Wilde; Fjoralba Zeka; Geneviève Laureys; Nadine Francotte; Gian Paolo Tonini; Simona Coco; Rogier Versteeg; Rosa Noguera; Johannes H. Schulte; Angelika Eggert; Raymond L. Stallings; Frank Speleman; Jo Vandesompele; Tom van Maerken

doi:https://doi.org/10.1371/journal.pone.0114696

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

Ali Rihani, Bram de Wilde, Fjoralba Zeka, Geneviève Laureys, Nadine Francotte, Gian Paolo Tonini, Simona Coco, Rogier Versteeg, Rosa Noguera, Johannes H. Schulte, Angelika Eggert, Raymond L. Stallings, Frank Speleman, Jo Vandesompele, Tom van Maerken

Research output: Contribution to journal › Article › Academic › peer-review

19 Citations (Scopus)

Abstract

Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide polymorphisms (SNPs) may help explain the heterogeneity of neuroblastoma and assist in identifying patients at higher risk for poor survival. SNPs in the TP53 pathway are of special importance, as several studies have reported associations between TP53 pathway SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. We selected 21 of the most frequently studied SNPs in the TP53 pathway and evaluated their association with outcome in 500 neuroblastoma patients using TaqMan allelic discrimination assays. We investigated the impact of 21 SNPs on overall survival, event-free survival, age at diagnosis, MYCN status, and stage of the disease in 500 neuroblastoma patients. A missense SNP in exon 10 of the CASP8 gene SNP D302H was associated with worse overall and event-free survival in patients with MYCN-amplified neuroblastoma tumors

Original language	English
Pages (from-to)	e114696
Journal	PLOS ONE
Volume	9
Issue number	12
DOIs	https://doi.org/10.1371/journal.pone.0114696
Publication status	Published - 2014

Access to Document

https://doi.org/10.1371/journal.pone.0114696

Cite this

Rihani, A., de Wilde, B., Zeka, F., Laureys, G., Francotte, N., Tonini, G. P., Coco, S., Versteeg, R., Noguera, R., Schulte, J. H., Eggert, A., Stallings, R. L., Speleman, F., Vandesompele, J., & van Maerken, T. (2014). CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients. PLOS ONE, 9(12), e114696. https://doi.org/10.1371/journal.pone.0114696

@article{1cd2fbc22d7649c3be2910ebd81bb87a,

title = "CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients",

abstract = "Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide polymorphisms (SNPs) may help explain the heterogeneity of neuroblastoma and assist in identifying patients at higher risk for poor survival. SNPs in the TP53 pathway are of special importance, as several studies have reported associations between TP53 pathway SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. We selected 21 of the most frequently studied SNPs in the TP53 pathway and evaluated their association with outcome in 500 neuroblastoma patients using TaqMan allelic discrimination assays. We investigated the impact of 21 SNPs on overall survival, event-free survival, age at diagnosis, MYCN status, and stage of the disease in 500 neuroblastoma patients. A missense SNP in exon 10 of the CASP8 gene SNP D302H was associated with worse overall and event-free survival in patients with MYCN-amplified neuroblastoma tumors",

author = "Ali Rihani and {de Wilde}, Bram and Fjoralba Zeka and Genevi{\`e}ve Laureys and Nadine Francotte and Tonini, {Gian Paolo} and Simona Coco and Rogier Versteeg and Rosa Noguera and Schulte, {Johannes H.} and Angelika Eggert and Stallings, {Raymond L.} and Frank Speleman and Jo Vandesompele and {van Maerken}, Tom",

year = "2014",

doi = "https://doi.org/10.1371/journal.pone.0114696",

language = "English",

volume = "9",

pages = "e114696",

journal = "PLOS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "12",

}

Rihani, A, de Wilde, B, Zeka, F, Laureys, G, Francotte, N, Tonini, GP, Coco, S, Versteeg, R, Noguera, R, Schulte, JH, Eggert, A, Stallings, RL, Speleman, F, Vandesompele, J & van Maerken, T 2014, 'CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients', PLOS ONE, vol. 9, no. 12, pp. e114696. https://doi.org/10.1371/journal.pone.0114696

TY - JOUR

T1 - CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

AU - Rihani, Ali

AU - de Wilde, Bram

AU - Zeka, Fjoralba

AU - Laureys, Geneviève

AU - Francotte, Nadine

AU - Tonini, Gian Paolo

AU - Coco, Simona

AU - Versteeg, Rogier

AU - Noguera, Rosa

AU - Schulte, Johannes H.

AU - Eggert, Angelika

AU - Stallings, Raymond L.

AU - Speleman, Frank

AU - Vandesompele, Jo

AU - van Maerken, Tom

PY - 2014

Y1 - 2014

N2 - Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide polymorphisms (SNPs) may help explain the heterogeneity of neuroblastoma and assist in identifying patients at higher risk for poor survival. SNPs in the TP53 pathway are of special importance, as several studies have reported associations between TP53 pathway SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. We selected 21 of the most frequently studied SNPs in the TP53 pathway and evaluated their association with outcome in 500 neuroblastoma patients using TaqMan allelic discrimination assays. We investigated the impact of 21 SNPs on overall survival, event-free survival, age at diagnosis, MYCN status, and stage of the disease in 500 neuroblastoma patients. A missense SNP in exon 10 of the CASP8 gene SNP D302H was associated with worse overall and event-free survival in patients with MYCN-amplified neuroblastoma tumors

AB - Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide polymorphisms (SNPs) may help explain the heterogeneity of neuroblastoma and assist in identifying patients at higher risk for poor survival. SNPs in the TP53 pathway are of special importance, as several studies have reported associations between TP53 pathway SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. We selected 21 of the most frequently studied SNPs in the TP53 pathway and evaluated their association with outcome in 500 neuroblastoma patients using TaqMan allelic discrimination assays. We investigated the impact of 21 SNPs on overall survival, event-free survival, age at diagnosis, MYCN status, and stage of the disease in 500 neuroblastoma patients. A missense SNP in exon 10 of the CASP8 gene SNP D302H was associated with worse overall and event-free survival in patients with MYCN-amplified neuroblastoma tumors

U2 - https://doi.org/10.1371/journal.pone.0114696

DO - https://doi.org/10.1371/journal.pone.0114696

M3 - Article

C2 - 25502557

SN - 1932-6203

VL - 9

SP - e114696

JO - PLOS ONE

JF - PLOS ONE

IS - 12

ER -